Evidence map›Paper›PMID 31863808›Full record

Trial reportThe Journal of allergy and clinical immunology2020

Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma.

Paul J Turner, Louise Fleming, Sejal Saglani, Jo Southern, Nick J Andrews, Elizabeth Miller, SNIFFLE-4 Study Investigators

Open access · hybridAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Paul J TurnerSection of Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom; Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom. Electronic address: p.turner@imperial.ac.uk.
Louise FlemingSection of Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
Sejal SaglaniSection of Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
Jo SouthernImmunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom.
Nick J AndrewsImmunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom.
Elizabeth MillerImmunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom.
SNIFFLE-4 Study Investigators
School of Advanced Study · GBPublic Health England · GBImperial College London · GB

Funding

Department of HealthMedical Research Council MR/K010468/1
6 · The paper itself

Abstract

backgroundLive attenuated influenza vaccine (LAIV) is recommended for annual influenza vaccination in children from age 2 years. However, some guidelines recommend against its use in children with asthma or recurrent wheeze due to concerns over its potential to induce wheezing.

objectiveWe sought to assess the safety of LAIV in children with moderate to severe asthma, and in preschool children with recurrent wheeze.

methodsProspective, multicenter, open-label, phase IV intervention study in 14 specialist UK clinics. LAIV was administered under medical supervision, with follow-up of asthma symptoms 72 hours and 4 weeks late, using validated questionnaires.

resultsA total of 478 young people (median, 9.3; range, 2-18 years) with physician-diagnosed asthma or recurrent wheeze were recruited, including 208 (44%) prescribed high-dose inhaled corticosteroids and 122 (31%) with severe asthma. There was no significant change in asthma symptoms in the 4 weeks after administration (median change, 0; P = .26, McNemar test), with no impact of level of baseline asthma control/symptoms in predicting either a worsening of asthma or exacerbation after LAIV using a regression model. A total of 47 subjects (14.7%; 95% CI, 11%-19.1%) reported a severe asthma exacerbation in the 4 weeks after immunization, requiring a short course of systemic corticosteroids; in 4 cases, this occurred within 72 hours of vaccination. No association with asthma severity, baseline lung function, or asthma control was identified.

conclusionsLAIV appears to be well tolerated in the vast majority of children with asthma or recurrent wheeze, including those whose asthma is categorized as severe or poorly controlled.

Indexed as

AdolescentAsthmaChildChild, PreschoolDisease ProgressionFemaleFollow-Up StudiesHumansInfluenza, HumanInfluenza VaccinesMaleOrthomyxoviridaeProspective StudiesRespiratory Function TestsRespiratory SoundsUnited KingdomInfluenza VaccinesVaccines, AttenuatedAsthmachildrenimmunizationinfluenzalive attenuated influenza vaccine

Identifiers

PMID31863808
PMCPMC7156909
OpenAlexW2995274127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.